Skip to main content
. 2022 Jun 15;177:68–80. doi: 10.1016/j.ejpb.2022.06.004

Fig. 2.

Fig. 2

Targeting assay in vitro. FACS assays (A): DCs being labeled with CD11c (a), DCs co-incubated with OVA@CD19-ILP (b), CT-26 cells co-incubated with OVA@CD11c-ILP (c), DCs co-incubated with OVA@CD11c-ILP (d), LCs co-incubated with CD11c (e) or OVA@CD11c-ILP (f). Targeting efficiency of OVA@CD11c-ILP in vitro (B). Targeting to LCs or DCs was evaluated by laser confocal microscopy (C): LCs incubated with OVA@CD11c-ILP (a); DCs incubated with OVA@CD11c-ILP (b); DCs incubated with OVA@CD19-ILP (c); CT-26 cells incubated with OVA@CD11c-ILP (d). The data were presented as mean ± sd (n = 3), *P＜0.05, **P＜0.01, ***P＜0.001.